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Recently we reported that 1,25-dihydroxyvitamin D, (I.25(OH),D,) through interaction with its specific receptor rapidly 
(within 1 min) stimulated intracellular cGMP production in cultured human skin fibroblasts. Here we show that this 
effect of 100 nM 1,25-(OH),D, is prevented by brief (30 min) inhibition of RNA synthesis (with actinomycin D or x- 
amanitin) or by brief inhibition of protein synthesis (with cycloheximide or diphtheria toxin). The protein synthesis inhibi- 
tors also blocked stimulation of cGMP by other steroids (testosterone or dexamethasone at 100 nM) but did not block 
cGMP stimulation by sodium nitroprusside. Since the time for the I,25(OH),D, receptor to increase cGMP seems too 
short to require de novo protein synthesis, we conclude that the 1,25-(OH),D, receptor acts together with rapidly turning 
over protein(s) to stimulate cGMP synthesis. 
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1. INTRODUCTION 
It is generally believed that receptor-mediated 
actions of 1,25dihydroxyvitamin D3 (1,25-(OH)z- 
Ds) require a 0.5-12 h induction interval, during 
which selected mRNA and protein concentrations 
begin to be modulated [l]. Transcriptional and 
translational effects of steroids may require pro- 
teins ancillary to the steroid receptor. Therefore, 
inhibitors of RNA and protein synthesis could 
block 1,25-(OH)zD3 genomic actions either by 
preventing de novo transcription and translation 
of mRNA or by preventing production of labile 
protein(s) participating in the processes of tran- 
scription or translation. Such ancillary proteins 
with rapid turnover have been suggested to par- 
ticipate in regulation of mRNA transcription by 
several v-ERB-A-related molecules, including the 
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receptors for progesterone [2], glucocorticoid [3], 
and triiodothyronine [4-61, 
1,25-(OH)zD,, like other steroids, can elicit ex- 
tremely rapid effects [7]. These rapid actions have 
generally been considered nongenomic and have 
sometimes been found to be independent of ongo- 
ing RNA and protein synthesis [8,9]. Recently, we 
found that 1,25-(OH)zDs, acting through an other- 
wise typical steroid receptor, elevated intracellular 
cGMP concentration in human skin fibroblasts 
within l-3 min [lo]. The short interval preceding 
the 1,25-(OHhD3 receptor-mediated rise in cGMP 
suggests that this action is not the result of altered 
mRNA or protein synthesis. We studied the effect 
of RNA and protein synthesis inhibitors on the 
1,25-(OH)zD3-mediated increase in cGMP. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Normal human skin fibroblasts were grown in Dulbecco’s 
minimal essential medium (Biofluids, Rockville, MD) sup- 
plemented with 10% defined fetal bovine serum (HyClone, 
Logan, UT), 0.2 mM glutamine, 80 mg/l gentamycin, and 
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0.1 pM insulin as in [lo]. Cells were plated at 400OO/vial to 
24-vial dishes and cultured for 24 h. 
2.2. Perturbation and measurement of cGMP 
Cells in 24-well plates were maintained in serum-free medium 
for 24 h. Then cells were preincubated for 30 min at 37°C with 
or without metabolic inhibitors in fresh serum-free media. Ac- 
tinomycin D (Sigma, St. Louis, MO) at 10 pg/ml or in other ex- 
periments 0.1 mg/ml cu-amanitin (Sigma) were used to inhibit 
RNA synthesis. Either 20pg/ml cycloheximide (Sigma) or 
50 nM diphtheria toxin (‘nicked’, Calbiochem, San Diego, CA) 
were used to inhibit protein synthesis. After this 30 min prein- 
cubation, monolayers were washed with Eagle’s no.2 medium 
without calcium, magnesium, sodium bicarbonate, and con- 
taining 25 mM Hepes and 2 mM manganese at pH 7.4. Then 
cells were incubated for 3-4 min at 37°C with and without 
agonists [1,25-(OH)lD3, testosterone, or dexamethasone at 
100 nM, or sodium nitroprusside at 1 mM] in the presence of 
0.1 mg/ml isobutylmethylxanthine. Reaction was stopped by 
removal of medium and addition of n-propanol. The cCMP 
content of vials was analyzed by a sensitive radioimmunoassay 
after acetylation [lo]. In each experiment cGMP was measured 
in wells without drug, in wells with metabolic inhibitor (in- 
hibitor of RNA or protein synthesis), in wells with cGMP 
agonist (a steroid or sodium nitroprusside), and in wells with 
metabolic inhibitor plus an agonist. Protein content was also 
measured (Biorad kit). 
2.3. Measurement of RNA synthesis 
Cells were incubated for 30 min with or without metabolic in- 
hibitor and then incubated for another 1 h in medium contain- 
ing 5 &i/ml [jH]uridine (NEN, DuPont, Boston; spec. act. 
27.5 Ci/mmol) without metabolic inhibitor. Then the reaction 
was stopped with removal of medium, and monolayers were 
washed with ice-cold phosphate-buffered saline. Acid-insoluble 
materials were precipitated by addition of 500~1 of 5% 
trichloroacetic acid solution and incubation for 2 h at 4°C. The 
dried precipitate was then solubilized with 1 N NaCl. Radioac- 
tivity was counted in a liquid scintillation counter and data were 
expressed as % of counts in control wells without inhibitor add- 
ed (mean & 1 SE). 
2.4. 1,25-(OH)zDj binding to soluble extracts from cells 
Immediately before being harvested, cells were incubated in 
fresh serum-free medium with or without actinomycin D 
(lOpg/ml) for 30 min. Hormone binding to soluble extracts 
was measured in triplicate aliquots in two separate experiments, 
as in [ll]. 
2.5. Statistics 
Results are shown as mean + SE. Paired t-test was used for 
data analysis. 
3. RESULTS 
3.1. Effects of transcription inhibitors on the 
rapid cGMP rise caused by I,25-(OH)ZDJ 
3 min incubation with 1,25-(OH)2D3 (100 nM) 
increased intracellular cGMP to 215 f 20% of con- 
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trol. Preincubation with actinomycin D for 30 min 
completely abolished this effect (fig.1). The same 
pretreatment did not affect sodium nitroprusside 
stimulation of cGMP. Preincubation with LY- 
amanitin decreased the stimulatory effect of 
1,25-(OH)2D3 on cGMP (P < 0.001) by 50% 
(fig.1). The same treatment did not influence the 
sodium nitroprusside effect on cGMP. Ac- 
tinomycin D or a-amanitin treatment without add- 
ed hormone increased the baseline intracellular 
cGMP concentration (165 f 15 and 133 f 5%, 
respectively; P ~0.005 and 0.01). 
30 min incubation with actinomycin D inhibited 
RNA synthesis down to 21 + 5% of control (mean 
of 3 experiments, each with 8 replicates). Similar 
treatment with a-amanitin inhibited RNA syn- 
thesis down to 54 + 12% (mean of two ex- 
periments, each with 8 replicates). 
3.2. Effects of protein synthesis inhibitors on the 
rapid cGMP rise caused by steroids 
In these experiments 1,25-(OH)2D3 increased in- 
tracellular cGMP concentration to 174 + 18 and 
188 + 16% of control. Preincubation with 
cycloheximide completely abolished this action 
(fig.2). The same preincubation affected neither 
the baseline cGMP value, nor the sodium 
nitroprusside effect. Preincubation with diphtheria 
toxin also inhibited the ability of 1,25-(OH)zD3 to 
increase cGMP (fig.2). Diphtheria toxin alone 
decreased the baseline cGMP concentration (to 71 
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Fig. 1. Effects of RNA synthesis inhibitors (AC, actinomycin D; 
AM, cu-amanitin) on l,25-(OH)zD, (D) and sodium 
nitroprusside (N) mediated increase of cGMP. Inhibitors were 
present during a 30 min preincubation; cGMP agonists were 
present for 3 min. Bars represent mean i 1 SE of 3 
experiments. Control cGMP value (C) was 70 + 4 pmol/mg 
protein. 
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Fig.2. Effects of protein synthesis inhibitors (Cy, 
cycloheximide; DT, diphtheria toxin) on I,25(OH)rDj (D) 
mediated increase of cGMP. Inhibitors were present during a 
30 min preincubation; cGMP agonists were present for 3 min. 
Bars represent mean k 1 SE of 2 experiments. Control cGMP 
value (C) was 58 + 5 pmol/mg protein. 
f 5%, P < 0.01) and slightly decreased the sodium 
nitroprusside effect (to 78 + 7%, P < 0.01). 
Cycloheximide or diphtheria toxin prevented the 
rapid stimulation of cGMP by testosterone or dex- 
amethasone (table 1). 
3.3. Effect of actinomycin D on 1,25-(OH)~DJ 
binding 
30 min incubation of fibroblasts with ac- 
tinomycin D did not change 1,25-(OH)zDs-binding 
capacity (2650 vs 2680 binding sites/cell with and 
Table 1 
Effects of protein synthesis inhibitors on the stimulation of 
intracellular cGMP by agonists 
cGMP regulator cGMP cCMP after cGMP after 
cycloheximide diphtheria 
toxin 
None lOOk 2 97* 12 16 k 3” 
Testosterone 
(100 nM) 148k 7 83 * 9b 79 + 7b 
Dexamethasone 
(100 nM) 189-+ 8 113 * 6b 76 + 7b 
Na nitroprusside 
(1 mM) 5460 k 320 5380 k 96 5000 f 172a 
a P < 0.01 for with vs without metabolic inhibitor 
b P < 0.001 for with vs without metabolic inhibitor 
Inhibitors of protein synthesis were preincubated with cells for 
30 min and incubation with cGMP agonists was for 4 min. 
Results (expressed as % of control) represent mean + 1 SE of 
2 experiments. Control cGMP concentration was 172 * 
11 pmol/mg protein 
without actinomycin D) or binding affinity (& = 
0.39 vs 0.34 nM). 
4. DISCUSSION 
We found that each of four metabolic inhibitors 
prevented the rapid stimulatory action of 
1,25-(OH)zD3 on intracellular cGMP. Ac- 
tinomycin D and a-amanitin inhibited this rapid 
action of 1,25-(OH)2D3 at concentrations that ef- 
fectively blocked RNA synthesis. It is unlikely that 
these effects we observed with RNA synthesis in- 
hibitors reflect general depression of cGMP 
metabolism, since, under our conditions of brief 
preincubation with metabolic inhibitors, these in- 
hibitors did not prevent the rise of cGMP caused 
by sodium nitroprusside. Actinomycin D or (Y- 
amanitin in fact stimulated cGMP, perhaps 
through generation of oxygen free radicals [ 121. 
We have shown here also that 30 min preincuba- 
tion with inhibitors of protein synthesis (cyclohex- 
imide or diphtheria toxin) blocked the 
1,25-(OH)zDj-mediated rise in cGMP. This in- 
hibitory effect is also unlikely to be the result of 
toxic effect on cGMP metabolism, because cGMP 
could still be increased by sodium nitroprusside. 
Since all four metabolic inhibitors prevented the 
cGMP rise by 1,25-(OH)zD3, and since the only 
common effect of these chemicals is the direct or 
indirect inhibition of protein synthesis, it is highly 
likely that inhibition of protein synthesis (and not 
some other ‘nonspecific’ effects of these metabolic 
inhibitors) accounts for their selective effects on 
1,25-(OH)zDs regulation of cGMP. 
Is it likely that the 1,25-(OH)zDs receptor itself 
is the rapidly turning over protein affected by the 
metabolic inhibitors in our study? Actinomycin D 
inhibited 1,25-(OH)zD3 receptor concentration 
during 20 h induction of receptor in kidney cells 
(LLC-PKl) [13]. Sher et al. [14] reported generally 
inhibitory effects on receptor concentration in 
human breast cancer cells (T47D) after 2-8 h in- 
cubation with inhibitors of transcription or of pro- 
tein synthesis. Since the 1,25-(OH)zD3 receptor has 
a half-life of approx. 4 h, we used only a brief ex- 
posure to actinomycin D (and other metabolic in- 
hibitors); with this brief preincubation, we did not 
find detectable ffect on receptor number or affini- 
ty. It seems unlikely that the receptor itself is the 
metabolic inhibitor-sensitive protein needed for 
209 
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hormonal stimulation of cGMP; however, we can- 
not exclude the possibility that a small pool of 
newly synthesized receptor is implicated. 
Our findings can be explained in one of two 
ways: (i) 1,25-(OH)zD3 acts through modulation of 
mRNA synthesis very rapidly thereby changing 
concentration of a cGMP-regulating protein, or 
(ii) a rapidly turning over message ncodes a rapid- 
ly turning over protein, which is necessary for a 
fast action of 1,25-(OH)zDs on cGMP. The first 
explanation is unlikely because the 1 min activa- 
tion time is not sufficient for induction of de novo 
protein synthesis. There was a prior suggestion for 
the involvement of a rapidly turning over protein 
in the slow 1,25-(OH)zDs effect to increase vitamin 
D-dependent calcium-binding protein mRNA syn- 
thesis in chick intestine, but a toxic effect of 
cycloheximide on total RNA synthesis was not ex- 
cluded [15]. 
The requirement for ancillary protein in this 
1,25-(OH)zDj receptor-mediated rapid increase of 
cGMP suggests a mechanism whereby the receptor 
could interact with an effector other than its 
putative DNA recognition element. The ancillary 
protein(s) could interact directly with the receptor, 
the effector, or both. A similar intermediary role 
has been suggested in glucocorticoid receptor in- 
duction of the rat m-acid glycoprotein gene; the 
promoter region of that gene lacks a consensus 
glucocorticoid recognition element, and the in- 
termediary protein may allow receptor-promoter 
interaction [3]. 
Rapidly turning over protein(s) has not been 
previously implicated in fast actions of 
1,25-(OH)ZDJ or other steroids. Our results in- 
dicate that the requirement for ongoing RNA and 
protein synthesis is not limited to 1,25-(OH)zD3 ef- 
fects with a long lag period, and that such a re- 
quirement need not imply a genomic 1,25-(OH)zD3 
action. Induction of spermidine Nr-acetyl- 
transferase occurs within 30 min of 1,25-(0H)zDs 
treatment, and actinomycin D or cycloheximide 
blocked this action [16]. This was interpreted as 
evidence for the involvement of extremely rapid de 
novo RNA and protein synthesis [ll], but our 
findings indicate that rapidly turning over pro- 
tein(s) with or without a genomic 1,25-(OH)zDs ac- 
tion are alternative possibilities. 
We showed previously that a rapid rise of cGMP 
in fibroblasts can be caused not only by 
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1,25-(OH)zD3 but also by androgens [lo]. Now we 
have found that a rapid cGMP rise can also be 
caused by dexamethasone. This rapid rise of 
cGMP caused by testosterone or dexamethasone, 
like that caused by 1,25-(OH)2D3, was also blocked 
by 30 min preincubation with protein synthesis in- 
hibitors. The similar effects of 1,25-(OH)zDj and 
other steroids on cGMP and the similar dependen- 
cy of all these steroid hormones on rapid protein 
turnover suggest involvement of a common pro- 
cess interacting with their receptors. The labile 
protein or proteins involved in one rapid action of 
the 1,25-(OH)2D3 receptor might not only be 
related to proteins mediating rapid effects of other 
steroids but also to proteins implicated in less rapid 
actions of these hormones [2-51. 
Acknowledgements: We are grateful to Drs Gerald Aurbach 
and Mark Nanes for useful discussions and to MS Wilma 
McKay for excellent technical assistance. 
REFERENCES 
[I] Duval, D., Durant, S. and Homo-Delarche, F. (1983) Bio- 
chim. Biophys. Acta 737, 409-442. 
[2] McKnight, G.S. (1987) Cell 14, 403-413. 
[3] Klein, ES., Reinke, R., Feigelson, P. and Ringold, M. 
(1987) J. Biol. Chem. 262, 520-523. 
[4] Hamblin, P.S., Santos, A., Wong, N.C.W., Schwartz, 
[51 
[61 
[71 
181 
[91 
[lOI 
[Ill 
WI 
1131 
[I41 
1151 
[I61 
H.L. and Oppenheimer, J.H. (1987) Mol. Endocrinol. 1, 
397-402. 
Wong, N.C.W., Schwartz, H.L., Santos, A. and 
Oppenheimer, J.H. (1987) Mol. Endocrinol. 1, 459-464. 
Santos, A., Perez-Castillo, A., Wong, N.C.W. and 
Oppenheimer, J.H. (1987) J. Biol. Chem. 262, 
16880-16884. 
Kumar, R. (1986) Kidney Int. 30, 793-803. 
Nemere, I. and Norman, W. (1987) J. Bone Min. Res. 2, 
99-107. 
Karsenty, G., Lacour, B., Ulmann, A., Pierandrei, E. 
and Drueke, T. (1985) Am. J. Physiol. 248, G40-G45. 
Barsony, J. and Marx, S.J. (1988) Proc. Natl. Acad. Sci. 
USA 85, 1223-1226. 
Lieberman, U.A., Eil, C. and Marx, S.J. (1983) J. Clin. 
Invest. 71, 192-200. 
Doroshow, J.H. (1983) Cancer Res. 43, 4543-4551. 
Costa, E.M., Hirst, M.A. and Feldman, D. (1985) 
Endocrinology 117, 2203-2210. 
Sher, E., Frampton, R.J. and Eisman, J.A. (1985) 
Endocrinology 116, 971-977. 
Theofan, G. and Norman, A.W. (1986) J. Biol. Chem. 
261, 7311-7315. 
Shinki, T., Takahashi, N., Kadofuku, T., Sato, T. and 
Suda, T. (1985) J. Biol. Chem. 260, 2185-2190. 
